Learn the tesamorelin ipamorelin dosing protocol used in research, including blend ratios, reconstitution, and frequency. This is not medical advice.
The tesamorelin ipamorelin dosing protocol commonly used in research involves daily subcutaneous injections, with tesamorelin typically dosed at 1–2 mg and ipamorelin at 100–300 mcg per injection. In a 5mg/5mg blend, a common research dose is 1–2 mg of the total blend per day, which delivers 0.5–1 mg of each peptide. This article summarizes reported protocols, reconstitution steps, and safety considerations for educational purposes only.
What Is the Tesamorelin and Ipamorelin Stack?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog. It is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone release without significantly affecting cortisol or prolactin.
When researchers combine tesamorelin and ipamorelin, they aim to target two different pathways for GH release. Tesamorelin acts on GHRH receptors, while ipamorelin acts on ghrelin receptors. This dual approach is sometimes studied for its potential synergistic effects on GH and IGF-1 levels.
It is important to note that ipamorelin is not FDA-approved for any human use. Tesamorelin is approved only for a specific condition, not for general wellness or fat loss.
Typical Tesamorelin and Ipamorelin Dosing Protocol
Dosing varies widely in research settings. The table below outlines common reported ranges for each peptide and for a 5mg/5mg blend.
| Compound | Typical Research Dose | Frequency | Notes |
|---|---|---|---|
| Tesamorelin alone | 1–2 mg | Once daily | Often injected subcutaneously at night |
| Ipamorelin alone | 100–300 mcg | 1–3 times daily | Often dosed before meals or before bed |
| 5mg/5mg blend (total 10 mg) | 1–2 mg of blend | Once daily | Delivers 0.5–1 mg tesamorelin + 0.5–1 mg ipamorelin |
| 10mg/5mg blend (tesamorelin/ipamorelin) | 1.5–3 mg of blend | Once daily | Higher tesamorelin ratio |
These ranges are not universal. Some protocols use tesamorelin at 2 mg daily, while others split ipamorelin into multiple smaller doses. The optimal ratio for a tesamorelin ipamorelin blend dose remains an open question in research.
Reconstitution, Timing, and Frequency
Reconstitution is the process of mixing lyophilized peptide powder with bacteriostatic water. A typical 5mg/5mg blend vial contains 5 mg of tesamorelin and 5 mg of ipamorelin, for a total of 10 mg of powder.
- Clean the vial tops with alcohol swabs.
- Draw 2–3 mL of bacteriostatic water into a syringe.
- Inject the water slowly against the vial wall to avoid foaming.
- Gently swirl; do not shake.
- Refrigerate after reconstitution and use within 2–4 weeks.
If you add 2 mL of water to a 10 mg total blend, each 0.1 mL contains 0.5 mg of total peptide (0.25 mg tesamorelin + 0.25 mg ipamorelin). A 1 mg dose would require 0.2 mL. Always calculate based on your specific vial and research goals.
The ipamorelin and tesamorelin together dosage schedule often follows the body’s natural GH rhythm. Most research protocols inject once daily, 30–60 minutes before bedtime, when endogenous GH peaks.
Some protocols split ipamorelin into 2–3 daily doses (morning, post-workout, bedtime) while keeping tesamorelin as a single nightly dose. Fasting for 2 hours before and after injection is sometimes recommended to avoid blunting GH release.
Consistency matters more than exact timing. The tesamorelin ipamorelin blend dosage per day reported on Reddit and forums varies, but a common starting point is 1 mg of a 5mg/5mg blend daily.
Comparing Tesamorelin and Ipamorelin to Other Peptides
Researchers often compare tesamorelin and ipamorelin to CJC-1295, sermorelin, and other GH secretagogues. The cjc-1295 ipamorelin protocol, for example, uses a GHRH analog plus a ghrelin agonist similar to the tesamorelin stack.
For a deeper comparison, see tesamorelin vs sermorelin vs ipamorelin. Sermorelin has a shorter half-life than tesamorelin, while ipamorelin is more selective than older ghrelin mimetics.
Some studies explore the cjc 1295 ipamorelin tesamorelin stack to combine three pathways. Others focus on fat-loss peptides like aod 9604 dosing protocol.
Safety, Legal Status, and Research Use
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy under the brand Egrifta. Ipamorelin is not FDA-approved for human use in the United States. Both are available for research purposes only.
Potential side effects of tesamorelin include injection site reactions, joint pain, and increased blood sugar. Ipamorelin may cause headaches or flushing. Long-term safety data for the combination is lacking.
This article is for educational purposes only and does not constitute medical advice. Anyone considering these peptides should consult a licensed healthcare professional.
FAQ
What is the typical tesamorelin ipamorelin blend dose?
A common research dose for a 5mg/5mg blend is 1–2 mg of the total blend per day, delivering 0.5–1 mg of each peptide. Doses vary by protocol and research goals.
Can I take tesamorelin and ipamorelin together?
In research settings, they are often combined, but no FDA-approved combination product exists. Ipamorelin is not approved for human use, and tesamorelin is approved only for HIV lipodystrophy.
How often should I inject tesamorelin ipamorelin?
Most protocols use once-daily injections, typically before bedtime. Some researchers split ipamorelin into multiple daily doses while keeping tesamorelin once daily.
Frequently Asked Questions
What is the typical tesamorelin ipamorelin blend dose?
A common research dose for a 5mg/5mg blend is 1–2 mg of the total blend per day, delivering 0.5–1 mg of each peptide. Doses vary by protocol and research goals.
Can I take tesamorelin and ipamorelin together?
In research settings, they are often combined, but no FDA-approved combination product exists. Ipamorelin is not approved for human use, and tesamorelin is approved only for HIV lipodystrophy.
How often should I inject tesamorelin ipamorelin?
Most protocols use once-daily injections, typically before bedtime. Some researchers split ipamorelin into multiple daily doses while keeping tesamorelin once daily.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.